A recent study indicates that targeting lower LDL cholesterol levels may significantly decrease the risk of major cardiovascular events for patients with atherosclerotic cardiovascular disease.
At the American College of Cardiology’s Annual Scientific Session (ACC.26), researchers presented findings from a pivotal study suggesting that more intensive treatment of low-density lipoprotein (LDL) cholesterol could lead to substantial reductions in cardiovascular risks. This study, known as Ez-PAVE, involved over 3,000 participants in South Korea, all of whom were diagnosed with atherosclerotic cardiovascular disease (ASCVD) and had an average age of 64.
The study divided participants into two groups: one targeting an LDL cholesterol level of less than 55 mg/dL, while the other aimed for a target of less than 70 mg/dL. Previous medical guidelines typically set the LDL cholesterol goal at 70 mg/dL, based on studies conducted two decades ago that linked this level to a decreased risk of recurrent cardiovascular events. However, this benchmark was largely established by coincidence rather than definitive evidence, leading many in the medical community to question whether a more aggressive target could yield better outcomes.
Understanding Cholesterol’s Role
Cholesterol plays a dual role in cardiovascular health, with high-density lipoprotein (HDL) cholesterol often termed “good” cholesterol and LDL cholesterol referred to as “bad” cholesterol. High levels of LDL cholesterol can lead to atherosclerosis, a condition characterized by the buildup of plaque in the arteries, which narrows blood vessels and increases the risk of heart attacks and strokes. Treatment for high LDL levels typically includes lifestyle changes, such as a heart-healthy diet and regular exercise, alongside medications designed to lower cholesterol levels.
Dr. Yu-Ming Ni, a cardiologist and lipidologist at MemorialCare Heart and Vascular Institute, noted that the research behind the traditional LDL cholesterol target has evolved, with more recent studies indicating that patients at very high risk might benefit from more aggressive LDL cholesterol management. The Ez-PAVE study aimed to address this emerging question: would all patients with existing heart disease benefit from a more stringent LDL cholesterol target?
Study Findings
After three years of follow-up, the study found that the composite endpoint—comprising cardiovascular death, nonfatal heart attacks, nonfatal strokes, and any revascularization or hospitalization for unstable angina—occurred in 6.6% of participants targeting less than 55 mg/dL compared to 9.7% in those aiming for under 70 mg/dL. This represented a 33% reduction in risk associated with the more aggressive LDL cholesterol target, predominantly driven by fewer nonfatal heart attacks and revascularizations.
Dr. Byeong-Keuk Kim, the lead author of the study and a professor at Severance Hospital at Yonsei University College of Medicine, emphasized the clinical significance of these results, stating that the findings support the notion that lowering LDL cholesterol to below 55 mg/dL could substantially reduce the risk of major cardiovascular events without compromising safety.
Implications for Clinical Practice
Dr. Ni remarked on the potential impact of the Ez-PAVE study on treatment strategies for heart and vascular disease, highlighting the importance of lowering LDL cholesterol levels to mitigate future cardiac events. He noted that while the difference in cholesterol targets was modest—only 10 mg/dL—the reduction in heart events was substantial, reinforcing the view that more aggressive treatment may be warranted.
In light of this study, Dr. Robert Fishberg, a cardiologist at Atlantic Health, expressed enthusiasm for the results, particularly as they align with the recently updated 2026 ACC/AHA Dyslipidemia Guidelines. These guidelines recommend lowering LDL cholesterol to below 70 mg/dL for all patients with ASCVD, with an optional goal of below 55 mg/dL. Fishberg pointed out that the Ez-PAVE trial’s findings reinforce the idea that aiming for the lower target significantly reduces cardiovascular events.
Despite the promising results, Fishberg highlighted a critical gap between clinical guidelines and actual treatment practices in the United States. According to a 2021 study published in the Gould Registry, only one in three patients with ASCVD achieved LDL cholesterol levels below 70 mg/dL, a statistic corroborated by multiple studies. He stressed the need for better education among healthcare providers and patients regarding the importance of achieving lower cholesterol targets for improved cardiovascular outcomes.
Conclusion
The Ez-PAVE study adds a significant piece to the puzzle of cardiovascular disease management, suggesting that an aggressive approach to lowering LDL cholesterol may be beneficial for patients with existing heart disease. Ongoing discussions within the medical community will likely focus on integrating these findings into clinical practice to enhance patient outcomes and reduce the burden of heart disease, the leading cause of mortality in the United States.
